Full REMAIN-1 pivotal study enrollment anticipated in summer 2025 ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Whether you’re on a weight loss journey of your own or not, you probably haven’t been able to avoid hearing about the sudden ...

Starting next month, the Food and Drug Administration will restrict who can make and sell popular weight-loss medications known as  GLP-1s.

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Drugs like Ozempic and Wegovy have the power to block the forces driving obesity, but the knock-on societal effects may not ...

Fact checked by Nick Blackmer Compounded versions of semaglutide, the active ingredient in weight loss drugs like Ozempic and ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...